Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy

References

• Silva AH, Locatelli C, Filippin-Monteiro FB, Martin P, Liptrott NJ, Zanetti-Ramos BG, et al. 2016. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. Toxicol Lett. 246:17–27.
   PubMed Web of Science ®Google Scholar
• Alexander-Bryant AA, van den Berg-Foels WS, Wen XJ. 2013. Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res. 118:1–59.
   PubMed Web of Science ®Google Scholar
• Chen HL, Wang YX, Zhou P, Liu R, Nan WB, Wang YS. 2014. Chitosan surface modified PLGA nanoparticle: preparation, characterization, in vitro drug release behavior and cytotoxicity. Curr Nanosci. 10:255–262.
   Web of Science ®Google Scholar
• Chen HL, Xie LQ, Qin JW, Jia YJ, Cai XH, Nan WB. 2016. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Colloids Surf B Biointerfaces. 138:1–9.
   PubMed Web of Science ®Google Scholar
• Chen HL, Yang WZ, Chen H, Liu LR, Gao FP, Yang XD. 2009. Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan. Colloids Surf B Biointerfaces. 73:212–218.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. ACS Nano. 3:16–20.
   PubMed Web of Science ®Google Scholar
• Fatemeh S, Abolfazl A, Morteza M, Zarghami N. 2016. Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells Nanomed Biotechnol. 44:423–430.
   PubMed Web of Science ®Google Scholar
• Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. 2014. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 27:83–92.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 42:419–436.
   PubMed Web of Science ®Google Scholar
• Giarra S, Serri C, Russo L, et al. 2016. Spontaneous arrangement of a tumor targeting hyaluronic acid shell on irinotecan loaded PLGA nanoparticles. Carbohydr Polym. 140:400–407.
   PubMed Web of Science ®Google Scholar
• Guo H, Zhang D, Li T, Li CY, Guo YY, Liu GP. 2014. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin. J Pharm Sci. 103:987–993.
   PubMed Web of Science ®Google Scholar
• Ju R, Li X, Shi J, Li XY, Sun MG, Zeng F. 2014. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 35:7610–7621.
   PubMed Web of Science ®Google Scholar
• Kristina BK, Helle N, Pramod K, Permin A, Gjetting T, Andresen TL. 2015. In vivo toxicity of cationic micelles and liposomes. Nanomed Nanotechnol Biol Med 11:467–477.
   PubMed Web of Science ®Google Scholar
• Laura C, Mara M, Maria FG, Cametti C, Laura CD, Mariella D. 2013. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures. Colloids Surf B Biointerfaces. 103:310–317.
   PubMed Web of Science ®Google Scholar
• Laura GF, Lalit HM, Dennis N, Hargrove D, Manautou J, Liang BT. 2016. Reduced in vivo toxicity of doxorubicin by encapsulation in cholesterol-containing self-assembled nanoparticles. Pharmacol Res. 107:93–101.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53:283–318.
   PubMed Web of Science ®Google Scholar
• Muhammad IS, Haliza K Mohd C, Shiow-Fern N, Mohd HZ, Fhataheya B. 2015. Minimization of local and systemic adverse effects of topical glucocorticoids by nanoencapsulation: in vivo safety of hydrocortisone–hydroxytyrosol loaded chitosan nanoparticles. J Pharm Sci. 104:4276–4286.
   PubMed Web of Science ®Google Scholar
• Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science. 311:622–627.
   PubMed Web of Science ®Google Scholar
• Paolo B, Aurelie S, Giovanna T, Giovagnoli S, Alessandro DM, Maurizio R. 2013. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int J Pharm. 454:316–323.
   PubMed Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. 2008. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Lett. 178:9–19.
   PubMed Web of Science ®Google Scholar
• Ruenraroengsak P, Cook J, Florence A. 2010. Nanosystem drug targeting: facing up to complex realities. J Control Release. 141:265–276.
   PubMed Web of Science ®Google Scholar
• Sedigheh FA, Abolfazl A, Mohammad RY, Zarghami F, Nejati-Koshki K, Zarghami N. 2016. Gene silencing effect of SiRNA-magnetic modified with biodegradable copolymer nanoparticles on hTERT gene expression in lung cancer cell line. Artif Cells Nanomed Biotechnol. 44:188–193.
   PubMed Web of Science ®Google Scholar
• Tang H, Li L, Chen H, Zhou ZM, Chen HL, Li XM. 2010. Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier. Drug Deliv. 17:552–558.
   PubMed Web of Science ®Google Scholar
• Vander R, Vehmeijer LJ, Kok RJ, Storm G, Gaal EVBV. 2013. Ligand-targeted particulate nanomedicines undergoing clinical evaluation. Curr Stat Adv Drug Deliv Rev. 65:1284–1298.
   PubMed Web of Science ®Google Scholar
• Vega-Villa KR, Takemoto JK, Yanez JA, Remsberg CM, Forrest ML, Davies Neal M. 2008. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev. 60:929–938.
   PubMed Web of Science ®Google Scholar
• Walter ER, Adriana P, Abuzar A, Lane MA, Aminabhavi TM. 2016. Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles. Carbohydr Polym. 147:323–332.
   PubMed Web of Science ®Google Scholar
• Xiong XY, Guo L, Gong YC, Li ZL, Li YP, Liu ZY. 2012. In vitro and in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction. Eur J Pharm Sci. 46:537–544.
   PubMed Web of Science ®Google Scholar
• Yu H, Tang Z, Zhang D, Song WT, Zhang Y, Yang Y. 2015. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J Control Release 205:89–97.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Chen HB, Zeng XM, Wang ZY, Zhang XD, Xu YP. 2014. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials. 35:2391–2400.
   PubMed Web of Science ®Google Scholar